Study summary · research use only
The CD36-PPARγ Pathway in Metabolic Disorders
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review (species not specified) discusses the CD36-PPARγ pathway in metabolic disorders, describing pharmacological activation of PPARγ as an approach explored for treating metabolic disorders, including current use of thiazolidinediones in diabetic patients to influence insulin resistance. The authors describe growth hormone releasing peptides (GHRP) as inducers of PPARγ through activation of the scavenger receptor CD36, and summarize reported associations between CD36 and the GHRP hexarelin in regulating PPARγ downstream actions relative to atherosclerosis, hepatic cholesterol biosynthesis, and fat mitochondrial biogenesis. The response of PPARγ coactivator PGC-1 in these processes is also discussed, and the GHRP-CD36-PPARγ pathway is described as a topic of interest for various tissue metabolic functions.
Abstract
Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.